ViiV Healthcare (GSK) Director, Access Strategy, Portfolio and Pipeline Innovation

Portfolio and lifecycle access strategy

• Lead US market access strategy for assigned portfolio and lifecycle priorities, including loss-of-exclusivity, indication expansion, formulation or dosing evolution, and other events that could materially affect access, reimbursement, or portfolio value.
• Lead the development of the US access strategy for products facing loss-of-exclusivity, integrating payer behavior, channel dynamics, competitor evolution, and implications for the broader ViiV portfolio.
• Ensure lifecycle strategies consider the interdependencies among oral treatment, long-acting treatment, prevention, emerging competitors, and future ViiV assets.
• Partner with brand-aligned Access Strategy Directors to ensure that portfolio-level recommendations translate into coordinated product strategies and execution.

Pipeline and commercialization strategy

• Serve as the US Market Access lead for assigned early- and late-stage pipeline assets, embedding payer, purchaser, provider, channel, and patient-access insights into development and commercialization strategies.
• Define the access ambition, critical success factors, and minimum and aspirational access requirements for pipeline assets in partnership with Global Market Access and US cross-functional stakeholders.
• Shape target product profiles, value propositions, evidence plans, pricing hypotheses, channel strategies, and launch assumptions from a US access perspective.
• Translate emerging long-acting treatment and next-generation PrEP concepts into actionable access hypotheses, including benefit design, site-of-care, acquisition, reimbursement, distribution, and patient-start considerations.

Policy and external-environment strategy

• Establish a structured process to monitor, assess, and communicate external developments that could affect ViiV's portfolio, including government pricing policy, Medicaid eligibility and financing changes, PBM and payer-model evolution, reimbursement reform, and channel consolidation.
• Translate external policy developments into product-level and portfolio-level implications, including potential effects on access, evidence needs, channel economics, and patient affordability.
• Develop scenario analyses and strategic recommendations for high-impact policy risks in partnership with cross-functional subject-matter experts in Government Relations.
• Provide senior leaders with concise, decision-oriented assessments of major external access developments rather than descriptive policy updates alone.